

**IND SAFETY REPORT: INITIAL WRITTEN REPORT****TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9849**

1. IND NUMBER

**7921**

2. AGENT NAME

**Bevacizumab (rhuMAb VEGF)**

3. DATE

**June 1, 2009**

4. SPONSOR

**Division of Cancer Treatment and Diagnosis, National Cancer Institute**

5. REPORTER'S NAME, TITLE, AND INSTITUTION

**Kevin Conlon, MD-Senior Investigator for Targeted Therapeutics III, Investigational Drug Branch, CTEP, DCTD, NCI**

6. PHONE NUMBER

**301-496-1196**

7. FAX NUMBER

**301-402-0428**

8. PROTOCOL NUMBER (AE #)

**GOG-0218 (AE # 1202538)**

9. PATIENT IDENTIFICATION

**109-0218-032**

10. AGE

**56**

11. SEX

**Female**

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 56-year-old female with ovarian epithelial cancer who experienced grade 4 ischemic colitis while on a phase 3 study using the investigational agent bevacizumab/placebo in combination with paclitaxel and carboplatin. She began her first course of treatment on March 23, 2009, and received the last doses of bevacizumab/placebo, paclitaxel, and carboplatin on May 13, 2009, (Cycle 3, Day 1). On May 17, 2009 (Cycle 3, Day 5), the patient reported having sudden lower abdominal pain and a gastrointestinal hemorrhage. On May 18, 2009 (Cycle 3, Day 6), she arrived at the hospital and reported having slight abdominal tenderness but did not present with bleeding. An x-ray of the abdomen was negative. Laboratory results showed an elevated WBC, c-reactive protein, and liver enzyme counts. On May 18, 2009 (Cycle 3, Day 6), the patient was admitted to the hospital. A CT scan revealed a hypertrophy of the bowel wall from the rectum to the descending colon. The patient was placed on antibiotics, IV fluids, and was placed on oral intake restrictions. On May 20, 2009 (Cycle 3, Day 8), the patient was removed from protocol. The patient remains hospitalized at this time. Additional information has been requested from the investigational site. There is a reasonable possibility that the adverse event may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE

**Bevacizumab/Placebo 15 mg/kg IV on Day 1, every 21 days, starting with cycle 2, for 5 cycles**

14. DATES OF TREATMENT

**The patient started Cycle 1, Day 1 of therapy on March 23, 2009, and received the last dose of bevacizumab/placebo on May 13, 2009 (Cycle 3, Day 1).**

15. ACCRUAL AND IND EXPERIENCE

**Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 21395. Colitis is known to be an expected event for bevacizumab, but more specifically, there have been 4 ischemic colitis incidences reported to the NCI through AdEERS as serious adverse events for bevacizumab.**

16. COMMENTS

**The following was also administered every cycle (Cycle = 21 days):**

**Paclitaxel: 175 mg/m<sup>2</sup> IV over 3 hours on day 1 × 6 cycles; last dose administered on May 13, 2009 (Cycle 3, Day 1)**

**Carboplatin: AUC 6 IV over 30 minutes on day 1 × 6 cycles; last dose administered on May 13, 2009 (Cycle 3, Day 1)**

**AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(D)(2).**

**DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**

0002